A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

BACKGROUND: Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union. METHODS: This 3-year follow-up study assessed the durability of sustained virologic response (SVR) (undetectable HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoulim, Fabien, Moreno, Christophe, Lee, Samuel S., Buggisch, Peter, Horban, Andrzej, Lawitz, Eric, Corbett, Chris, Lenz, Oliver, Fevery, Bart, Verbinnen, Thierry, Shukla, Umesh, Jessner, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789677/
https://www.ncbi.nlm.nih.gov/pubmed/29378602
http://dx.doi.org/10.1186/s12985-018-0936-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789677/
https://www.ncbi.nlm.nih.gov/pubmed/29378602
http://dx.doi.org/10.1186/s12985-018-0936-4

Ejemplares similares